|
Back to Home » January 2017 News » Biogen exercises option to enter into exclusive, worldwide License Agreement for Factor IX utilizing Amunix' XTEN(R) half-life extension technology |
Biogen exercises option to enter into exclusive, worldwide License Agreement for Factor IX utilizing Amunix' XTEN(R) half-life extension technology |
January 06, 2017
MOUNTAIN VIEW, CA--(Marketwired - January 05, 2017) - Amunix Operating Inc. announced today that Biogen (NASDAQ: BIIB) has exercised its option to enter into an exclusive, worldwide license agreement to develop and commercialize a novel, recombinant Factor IX product candidate that incorporates Amunix' XTEN technology to provide extended half-life. The agreement is part of Biogen's hemophilia business, which is expected to launch as Bioverativ on February 1, 2017 as an independent, public company focused on the discovery, research, development and commercialization of treatments for hemophilia and other rare blood disorders.
Source URL: http://www.marketwired.com/mw/release.do?id=2186539&sourceType=3
|
|
|
|
